Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 434

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

Open access
Zviran, Asaf, Schulman, Rafael C., Shah, Minita, Hill, Steven T. K., Deochand, Sunil, Khamnei, Cole C., Maloney, Dillon, Patel, Kristofer, Liao, Will, Widman, Adam J., Wong, Phillip, Callahan, Margaret K., Ha, Gavin, Reed, Sarah, Rotem, Denisse, Frederick, Dennie, Sharova, Tatyana, Miao, Benchun, Kim, Tommy, Gydush, Greg, Rhoades, Justin, Huang, Kevin Y., Omans, Nathaniel D., Bolan, Patrick O., Lipsky, Andrew H., Ang, Chelston, Malbari, Murtaza, Spinelli, Catherine F., Kazancioglu, Selena, Runnels, Alexi M., Fennessey, Samantha, Stolte, Christian, Gaiti, Federico, Inghirami, Giorgio G., Adalsteinsson, Viktor, Houck-Loomis, Brian, Ishii, Jennifer, Wolchok, Jedd D., Boland, Genevieve, Robine, Nicolas, Altorki, Nasser K., Landau, Dan A.·2020·Nature Medicine

Abstract

In many areas of oncology, we lack sensitive tools to track low-burden disease. Although cell-free DNA (cfDNA) shows promise in detecting cancer mutations, we found that the combination of low tumor fraction (TF) and limited number of DNA fragments restricts low-disease-burden monitoring through the prevailing deep targeted sequencing paradigm. We reasoned that breadth may supplant depth of sequencing to overcome the barrier of cfDNA abundance. Whole-genome sequencing (WGS) of cfDNA allowed ultra-sensitive detection, capitalizing on the cumulative signal of thousands of somatic mutations observed in solid malignancies, with TF detection sensitivity as low as 10−5. The WGS approach enabled dynamic tumor burden tracking and postoperative residual disease detection, associated with adverse outcome. Thus, we present an orthogonal framework for cfDNA cancer monitoring via genome-wide mutational integration, enabling ultra-sensitive detection, overcoming the limitation of cfDNA abundance and empowering treatment optimization in low-disease-burden oncology care. A new approach for whole-genome sequencing of plasma circulating tumor DNA allows for dynamic monitoring of disease burden and ultra-sensitive detection of minimal residual disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0915-3

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 434

Metadata

Authors
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., Maloney, D., Patel, K., Liao, W., Widman, A. J., Wong, P., Callahan, M. K., Ha, G., Reed, S., Rotem, D., Frederick, D., Sharova, T., Miao, B., Kim, T., Gydush, G., Rhoades, J., Huang, K. Y., Omans, N. D., Bolan, P. O., Lipsky, A. H., Ang, C., Malbari, M., Spinelli, C. F., Kazancioglu, S., Runnels, A. M., Fennessey, S., Stolte, C., Gaiti, F., Inghirami, G. G., Adalsteinsson, V., Houck-Loomis, B., Ishii, J., Wolchok, J. D., Boland, G., Robine, N., Altorki, N. K., & Landau, D. A.
Venue
Nature Medicine
Published
2020-06-01
Volume
26
Issue
7
Pages
1114-1124
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3028644610
Cited by
434
References
48
FWCI
16.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. https://app.cochat.ai/papers/10.1038/s41591-020-0915-3
The paper
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., Maloney, D., Patel, K., Liao, W., Widman, A. J., Wong, P., Callahan, M. K., Ha, G., Reed, S., Rotem, D., Frederick, D., Sharova, T., Miao, B., Kim, T., . . . Landau, D. A. (2020). Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine. https://doi.org/10.1038/s41591-020-0915-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.